Actavis on Wednesday announced that its subsidiary Forest Labs has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug, following approval.
As many as 32 organizations on Tuesday signed a letter calling on the Food and Drug Administration to require biologics and biosimilars to have the same International Nonproprietary Name, a practice currently in use in Europe and other markets.
Upsher-Smith Laboratories on Wednesday announced the launch of testosterone gel (1%), the generic of Vogelxo (testosterone) gel 1%, for topical use. Newly approved by the Food and Drug Administration, it is the first and only available generic testosterone replacement therapy available in three configurations, the company stated.
Actavis on Monday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets.
The Food and Drug Administration on Thursday notified health professionals, their provider organizations and caregivers for infants, that prescription oral viscous lidocaine 2% solution should not be used to treat infants and children with teething pain.
Ohm Labs, a wholly owned subsidiary of Ranbaxy Labs, on Friday announced that it received approval from the Food and Drug Administration to manufacture and market valsartan tablets in 40 mg, 80 mg, 160 mg and 320 mg dosage strengths.
The Advisory Committee on Immunization Practices on Wednesday voted to recommend a preference for using the nasal spray flu vaccine instead of the flu shot in healthy children ages 2 years to 8 years of age when it is immediately available.
The Congressional Wellness Caucus and the Partnership to Fight Chronic Disease on Thursday hosted a briefing to examine the impact of chronic, non-communicable disease and look beyond just medical costs to more holistically consider total productivity, particularly among the federal workforce.
Slightly more than half of all seniors who are not in an assisted living situation reported having issues with incontinence, according to a report released Wednesday by the Centers for Disease Control and Prevention.
Patients with chronic obstructive pulmonary disease may need more education and better dialogue with their physicians to effectively manage the progressive respiratory condition, according to key findings from a two-part national COPE (Chronic Obstructive Pulmonary Experience) Survey initiative released last week by the COPD Foundation.
After a five-year contraction in employer healthcare spending growth, medical inflation in the United States is projected to rise to 6.8% in 2015, according to PricewaterhouseCoopers’ Health Research Institute.
Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.